Ignaseclant, NMD Pharma’s experimental oral therapy, may help improve muscle strength and motor function in people with Charcot-Marie-Tooth disease (CMT) by making muscles respond better to weaker nerve signals. That’s according to top-line data from the Phase 2a SYNAPSE-CMT trial (NCT06482437), which also showed consistency in…